Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Published:2020-07 Issue:1 Volume:1 Page:113-121
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Foureau David M.¹^ORCID,Bhutani Manisha²,Robinson Myra³,Guo Fei¹,Pham Duy⁴,Buelow Ben⁴,Steuerwald Nury⁵,Rigby Katherine⁶,Tjaden Elise⁶,Leonidas Marina¹,Paul Barry A.²,Atrash Shebli²,Ndiaye Ami²,Symanowski James T.³,Voorhees Peter M.²,Usmani Saad Z.²

Affiliation:

1. Immune Monitoring Core LaboratoryLevine Cancer Institute/Atrium Health Charlotte North Carolina USA

2. Department of Hematologic Oncology and Blood DisordersLevine Cancer Institute/Atrium Health Charlotte North Carolina USA

3. Department of Cancer BiostatisticsLevine Cancer Institute/Atrium Health Charlotte North Carolina USA

4. TeneoBio Menlo Park California USA

5. Molecular Biology Core LaboratoryLevine Cancer Institute/Atrium Health Charlotte North Carolina USA

6. Hematology Oncology Translational Research LaboratoryLevine Cancer Institute/Atrium Health Charlotte North Carolina USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.69

Reference21 articles.

1. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

2. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

3. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

4. Treatment with AMG 420, an anti‐B‐cell maturation antigen (BCMA) bispecific T‐cell engager (BiTe) antibody construct, induces minimal residual disease (MRD) negative complete response in relapsed and/or refractory (R/R) multiple myeloma (MM) patients: results of a first in human (FIH) phase I dose escalation study;Topp MS;Blood.,2018

5. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

2. Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy;Cancers;2024-07-06

3. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31

4. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives;Frontiers in Oncology;2024-04-10

5. A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models;Scientific Reports;2024-03-01